SAMSUNG PHARM. Co., LTD. (KRX:001360)
South Korea
· Delayed Price · Currency is KRW 1,508.00
+4.00 (0.27%)
At close: Apr 16, 2025, 3:30 PM KST
SAMSUNG PHARM. Co., LTD. Revenue
In the year 2024, SAMSUNG PHARM. Co., LTD. had annual revenue of 44.29B KRW, down -4.71%. SAMSUNG PHARM. Co., LTD. had revenue of 23.34B in the quarter ending September 30, 2019, with 122.70% growth.
Revenue
44.29B
Revenue Growth
-4.71%
P/S Ratio
3.20
Revenue / Employee
184.56M
Employees
240
Market Cap
141.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | -2.19B | -4.71% |
| Dec 31, 2018 | 46.48B | 4.56B | 10.89% |
| Dec 31, 2017 | 41.92B | -5.27B | -11.18% |
| Dec 31, 2016 | 47.19B | 5.03B | 11.93% |
| Dec 31, 2015 | 42.16B | 11.88B | 39.21% |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
| Dec 31, 2009 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| LigaChem Biosciences | 125.90B |
| Peptron | 3.15B |